Genus Oncology has dosed the first patient in a Phase I trial to evaluate its GO-203-2c compound as a treatment for solid tumours.
The prospective, open-label trial is designed to determine the safety, tolerability and potential anti-tumour activity of GO-203-2c.
Go deeper with GlobalData
Up to 40 patients will be enrolled at multiple clinical sites.
GO-203-2c is the optimised lead peptide drug candidate, synthesised to target MUC1, an oncoprotein that is over-expressed in many human carcinomas.
Genus has also filed an investigational new drug application with the US Food & Drug Administration.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
